Aerogen®
Revolutionizing respiratory care, Aerogen® delivers unparalleled aerosol drug delivery solutions designed to optimize patient treatment and clinical efficiency. Our advanced technology ensures precise, effective medication delivery, transforming the standard of care for patients across all ages and acuity levels.
Enhanced Patient Outcomes
Experience superior drug deposition with our high-performance nebulizers, leading to faster symptom relief and improved patient recovery across a wide range of respiratory conditions.
Unmatched Clinical Efficiency
Streamline treatment protocols and reduce therapy times with our intuitive, easy-to-integrate systems, allowing healthcare professionals to focus more on patient care and less on complex procedures.
Proven Reliability & Safety
Place your trust in a globally recognized leader for consistent, accurate, and safe medication delivery. Our closed-system technology minimizes drug waste and environmental contamination, supporting a safer clinical environment.
For more information, please contact us:
Phone: +91 8019962424
Email: info@reachmedicalsystems.com
Phone: +91 8019962424
Email: info@reachmedicalsystems.com
Elevating Care: Advanced Aerosol Drug Delivery for Chronic Obstructive Pulmonary Disease (COPD)1-5
Chronic Obstructive Pulmonary Disease (COPD) devastates millions globally, standing as a primary cause of suffering and premature death. As the worldwide impact of this relentless respiratory condition intensifies, the imperative for highly effective treatment strategies and unparalleled drug delivery systems becomes undeniable. Aerogen delivers on this critical need, enabling optimal patient outcomes.
212M
Global Reach
Lives impacted: 212 million people worldwide living with COPD, highlighting a vast and critical patient population based on 2019 data.
74.4M
Profound Disability
Burden of disease: 74.4 million Disability-Adjusted Life Years (DALYs) lost to COPD globally in 2019, underscoring the profound impact on quality of life and productivity.
3.3M
Annual Devastation
Tragic toll: 3.3 million deaths attributed to COPD worldwide annually in 2019, emphasizing the urgent need for optimized treatment delivery.
Transforming COPD Management: Overcoming Aerosol Therapy Challenges for Superior Patient Care
While aerosol therapy remains the cornerstone of pharmacological COPD treatment, delivering vital bronchodilators and corticosteroids directly to the airways, its full potential is often hampered by critical clinical challenges. Addressing these obstacles is paramount to unlocking optimal therapeutic outcomes and enhancing the quality of life for millions.7
Navigating Device Complexity
Proper inhaler technique demands coordination, manual dexterity, and cognitive ability—factors frequently compromised in elderly or acutely ill patients. Overcoming these usability barriers is key to ensuring consistent medication delivery and patient adherence.
Mitigating Safety Concerns
The practice of opening ventilator circuits for medication delivery introduces significant infection control risks through fugitive aerosol emissions. Innovating closed-system solutions is vital for safeguarding both patients and healthcare providers.
Ensuring Consistent Delivery Across Care Levels
Maintaining effective and precise aerosol delivery across varying levels of respiratory support presents a complex challenge. Solutions that ensure seamless performance from standard care to intensive support are critical for comprehensive patient management.
Unlocking Full Therapeutic Potential: Overcoming Inhaler Technique Barriers in COPD Management
Achieving optimal medication delivery is paramount for effective COPD treatment, directly influencing patient outcomes, reducing exacerbations, and enhancing quality of life. However, critical patient factors frequently compromise correct inhaler technique, leading to suboptimal drug delivery and diminished therapeutic benefits. Age-related physiological changes, reduced manual dexterity, cognitive impairments, and coordination difficulties disproportionately affect elderly COPD patients and those in acute exacerbation. These pervasive challenges underscore an urgent need for innovative solutions that guarantee precise and consistent medication administration, regardless of patient limitations.7
Eliminating Coordination & Timing Hurdles
Current devices often demand intricate coordination, a significant barrier for many patients. Our solution simplifies the process, ensuring consistent drug delivery without reliance on complex maneuvers or perfect timing.
Mitigating Physical Limitations for All Patients
Patients with reduced manual dexterity struggle with conventional inhalers. Our design prioritizes ease of use, accommodating varying physical abilities to ensure every patient can effectively administer their medication.
Bridging Cognitive Gaps for Reliable Treatment
Cognitive impairments can lead to errors in technique. We offer intuitive, straightforward operation that reduces the cognitive load, ensuring patients adhere to therapy and achieve full clinical benefits.
Reducing the Burden of Repetitive Patient Education
The constant need for re-education strains healthcare resources. Our user-friendly system inherently guides proper technique, minimizing educational demands and freeing up valuable clinician time.
Challenge 2: Protecting Healthcare Teams and Patients from Fugitive Emissions
Critical Threat: Infection Control Risks
Traditional methods require opening pressurized ventilator circuits, introducing significant vulnerabilities for infection transmission to both patients and staff. Our solution is engineered to eliminate this exposure, safeguarding your critical care environment.
Enhanced Safety: Addressing Fugitive Aerosol Concerns
The escape of medication particles into the ambient environment during mechanical ventilation poses serious risks to healthcare worker safety and contributes to environmental contamination. Our innovative approach drastically reduces fugitive aerosol emissions, ensuring a safer workspace and compliance with environmental standards.8-10
Uncompromised Care: Minimizing Circuit Disruption
Maintaining an intact ventilator circuit is paramount. Minimizing disruption is essential for both patient safety and stringent infection control protocols in the ICU. Our technology supports seamless medication delivery without compromising critical circuit integrity.
Challenge 3: Optimizing Support During Escalation of Care
During critical COPD exacerbations, patients require seamless, effective aerosol therapy even as respiratory support escalates. The challenging transition across modalities—from high-flow oxygen to non-invasive (NIV) and invasive mechanical ventilation (IMV)—necessitates a drug delivery solution that guarantees uninterrupted efficacy and patient safety at every stage.
High-Flow Therapy (HF)
Crucial for early intervention, requiring precise and consistent medication delivery.
Non-Invasive Ventilation (NIV)
Demanding consistent therapy and patient comfort without compromising ventilatory support.
Invasive Mechanical Ventilation (IMV)
Where optimal drug deposition is paramount for critically ill patients and complex circuit integrity.
How Aerogen Delivers Unrivaled Performance Across All Levels of Care
Enter Aerogen. Our clinically proven vibrating mesh nebulizer technology is specifically engineered to revolutionize aerosol drug delivery. It's the unrivaled solution for overcoming traditional limitations, ensuring optimal therapeutic effect across the entire continuum of respiratory care, even during the most challenging escalations. Maximize drug delivery and minimize patient discomfort with Aerogen.
The study by Joyce et al. was performed in an in-vitro model of invasive mechanical ventilation.
Unlocking Superior Outcomes: Clinical Evidence in COPD Management
Aerogen's innovative technology is not just supported, but proven by robust clinical data, consistently demonstrating superior drug delivery and significantly improved patient outcomes in critical COPD management scenarios.
Aerogen Delivers Unmatched Drug Efficacy³
In a pivotal clinical study, Aerogen showcased its competitive advantage in patients with stable moderate-to-severe COPD requiring non-invasive ventilation. Our technology achieved significantly superior lung deposition compared to conventional jet nebulization, ensuring medication reaches where it's needed most for maximum therapeutic impact.
Mean (±SD) lung deposition: 12.05 ± 2.96% vs 3.14 ± 1.71%; P<0.001
4x
Maximize Therapeutic Benefit
Aerogen provides a 4-fold increase in medication delivered directly to the lungs during NIV, a critical advantage over traditional jet nebulizers. This enhanced delivery translates to more effective treatment and improved patient response.³
Aerogen: Driving Superior Bronchodilator Response,
For patients experiencing acute COPD exacerbations, the choice of nebulizer can significantly impact recovery. When bronchodilator therapy was delivered via Aerogen in patients requiring NIV, it consistently produced significant and clinically meaningful improvements across a spectrum of vital clinical parameters compared to jet nebulization. Ensure your patients receive the most effective treatment for faster, better outcomes.
Experience Broad Clinical Impact:
- Forced expiratory volume in 1 second (FEV1): Demonstrates improved airway function.
- Forced vital capacity (FVC): Indicates enhanced lung capacity.
- Dyspnea score (Borg scale): Quantifies significant reduction in shortness of breath.
- Respiratory rate (RR): Reflects improved breathing efficiency.
- Partial pressure of carbon dioxide (PaCO2): Shows better gas exchange and reduced respiratory distress.
Between-group differences at 60 and 120 minutes: FEV1, P<0.001; FVC, P<0.001; Borg score, P<0.007; PaCO2, P<0.004⁴
Revolutionizing Respiratory Care: The Aerogen Product Portfolio
Aerogen Solo: Precision Aerosol Delivery for Critical Care
The Aerogen Solo system stands as the gold standard for reliable and efficient aerosol therapy in ventilated and high-flow patients. Its advanced closed-circuit design not only ensures optimal drug efficacy but also champions patient safety and infection control, setting a new benchmark in respiratory medication delivery.
Rapid Deployment & Intuitive Setup
Seamlessly integrates into clinical workflows with minimal training, maximizing efficiency in critical care environments.
Whisper-Quiet Operation
Creates a tranquil therapeutic experience for patients, minimizing distress and promoting a calm recovery.
Enhanced Infection Control
Single-patient-use design drastically reduces the risk of cross-contamination, protecting both patients and staff.
Flexible & Prolonged Therapy
Offers versatile treatment protocols with 28 days of intermittent or 7 days of continuous use, adapting to diverse patient needs.
Preserves Ventilator Performance
Delivers medication without requiring additional gas flow, maintaining optimal ventilation and patient synchrony.
Secure Medication Refill
Facilitates safe medication refills without compromising circuit integrity, significantly reducing exposure to fugitive emissions.
Aerogen Ultra: Empowering Self-Ventilating Patients
The Aerogen Ultra redefines portable, effective aerosol delivery for self-ventilating patients. Engineered for maximum drug optimization and unparalleled patient comfort, it combines innovative features with user-centric design to ensure superior therapeutic outcomes wherever care is needed.
Integrated Oxygen Support
Features an optional O2 delivery port for seamless supplemental oxygen administration alongside aerosol therapy.
Optimized Airflow Control
Ergonomic valved mouthpiece provides precise airflow regulation, enhancing drug deposition and patient compliance.
Efficient Aerosol Reservoir
Innovative chamber design creates a dedicated aerosol reservoir, ensuring consistent and targeted medication delivery.
Enhanced Compatibility
Extended mouthpiece allows for seamless integration with filtration systems, broadening clinical applications.
The Aerogen Ultra with extended mouthpiece is only available in selected regions. Refer to the relevant instruction manual for your region to determine availability.
Elevate Patient Outcomes. Discover Aerogen.
Download Our Comprehensive COPD Clinical Factsheet
Evidence-Based Insights for Superior Patient Outcomes
Access our detailed clinical factsheet featuring peer-reviewed research, comparative efficacy data, and evidence-based protocols for COPD management with Aerogen technology. This comprehensive resource provides healthcare professionals with the clinical insights needed to optimize aerosol drug delivery and improve patient outcomes.
Clinical study results and comparative data
Evidence-based treatment protocols
Safety and efficacy profiles
Implementation guidelines for healthcare teams
Aerogen®
Revolutionizing Respiratory Care with Advanced Aerosol Delivery
Unmatched Drug Delivery Efficiency
Ensure optimal medication deposition to the lungs, maximizing therapeutic impact and patient outcomes with Aerogen's precision technology.
Enhanced Patient Safety & Comfort
Our closed-circuit design minimizes contamination risk and offers virtually silent operation, providing a safer, more comfortable experience for critically ill and self-ventilating patients.
Streamlined Clinical Workflow
With quick setup, no added flow requirements, and the ability to refill medication without opening the circuit, Aerogen simplifies procedures for healthcare professionals.
Abbreviations
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PaCO2, partial pressure of carbon dioxide; SV, self-ventilating.
References
1. 30-354 Rev U Aerogen Solo System Instruction Manual.
2. Li J, et al. Respiration. 2019;98(5):401-409.
3. Galindo-Filho VC, et al. Respir Med. 2019;153:60-67.
4. Avdeev SN, et al. J Aerosol Med Pulm Drug Deliv. 2021;34(6):358-365.
5. Beuvon C, et al. Respir Care. 2021;respcare.09242.
6. Safiri S, et al. BMJ. 2022;378:e069679.
7. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for prevention, diagnosis and management
of COPD, 2023. Available at: www.goldcopd.org/2023-gold-report-2. Accessed: May 2023.
8. Joyce M, et al. Pharmaceutics. 2021;13(2):199.
9. O'Toole C, et al. Ann Transl Med. 2021;7(7):592.
10. Fink JB, et al. J Aerosol Med Pulm Drug Deliv. 2020;33(6):300-304.
11. 30-1487 Rev A Aerogen Ultra Instruction Manual.Contact Us
+91 8019962424
info@reachmedicalsystems.com
Ready to elevate your respiratory care standards?